Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 0.89 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.54 |
| ▸ | CTSD | P07339 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21067614 | 0.94 | BACE1 (1.00) | BACE1BACE2CTSD | |
| SCHEMBL4141578 | 0.94 | BACE1 (1.00) | BACE1BACE2CTSD | |
| SCHEMBL4201012 | 0.92 | BACE1 (0.76) | BACE1BACE2CTSD | |
| SCHEMBL13879668 | 0.89 | BACE1 (0.82) | BACE1BACE2CTSD | |
| Hydrochloric Acid SCHEMBL4286079 | 0.89 | BACE1 (0.81) | BACE1BACE2CTSD | |
| SCHEMBL4146578 | 0.87 | BACE1 (0.87) | BACE1BACE2 | |
| SCHEMBL4135087 | 0.87 | BACE1 (0.75) | BACE1 | |
| SCHEMBL4147959 | 0.87 | BACE1 (0.75) | BACE1 | |
| SCHEMBL4136802 | 0.86 | BACE1 (0.78) | BACE1BACE2CTSD | |
| SCHEMBL4148117 | 0.86 | BACE1 (0.77) | BACE1BACE2CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090062282-A1 | Substituted Amino-Pyrimidones and Uses Thereof | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | US | claimed |
| US-20090221579-A1 | Substituted Amino-Compounds and Uses Thereof | ASTEX THERAPEUTICS (GB) | 2009-09-03 | — | — | US | disclosed |
| US-20090221579-A1 | Substituted Amino-Compounds and Uses Thereof | ASTEX THERAPEUTICS (GB) | 2009-09-03 | — | — | US | disclosed |
| US-20090221579-A1 | Substituted Amino-Compounds and Uses Thereof | ASTEX THERAPEUTICS (GB) | 2009-09-03 | — | — | US | disclosed |
| US-20090062282-A1 | Substituted Amino-Pyrimidones and Uses Thereof | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | US | disclosed |
| US-20090062282-A1 | Substituted Amino-Pyrimidones and Uses Thereof | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | US | disclosed |
| US-20090062282-A1 | Substituted Amino-Pyrimidones and Uses Thereof | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221579-A1 | Substituted Amino-Compounds and Uses Thereof | APP, PSEN1, BACE1 | BACE1 3/4885BACE2 7/4885CTSD 857/4885 |
| US-20090062282-A1 | Substituted Amino-Pyrimidones and Uses Thereof | APP, PSEN1, PSEN2 | BACE1 4/4885BACE2 8/4885CTSD 1616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.